Clinical Trials Logo

Pancreatic Cancer, Resected clinical trials

View clinical trials related to Pancreatic Cancer, Resected.

Filter by:
  • None
  • Page 1

NCT ID: NCT02261714 Completed - Clinical trials for Pancreatic Cancer, Resected

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and - Understand any possible side effects of the additional use of TG01/GM-CSF with gemcitabine - Investigate whether TG01/GM-CSF when given with gemcitabine can produce an immune response - Investigate if the treatment can delay or reduce recurrence of the disease